PRUNE2 and prostate cancer: As compared with normal prostate, we found that prostate cancer showed consistent increased expression of PCA3 and consistent decreased expression of PRUNE2 in tumors across a broad range of pathological attributes (i.e., Gleason grades, scores, groups, and stages) in both patient cohorts.